title: [Chemotherapy for small-cell lung cancer (SCLC) patients with renal failure].
abstract: We administered chemotherapy in three cases of small-cell lung cancer (SCLC) with renal failure under different situations. Hemodialysis (HD) was used in 2 out of the 3 cases. Case 1 was complicated by acute renal failure from extensive bilateral tumor invasion. After chemotherapy (CBDCA + ETP) under HD, renal metastases regressed and renal function improved, although the final response was PD. In case 2, HD had been introduced for diabetic nephropathy. After 2 cycles of chemotherapy (CBDCA + ETP) under HD, the patient attained a PR. Case 3 is an example of paraneoplastic nephrotic syndrome with renal failure. Chemotherapy including CBDCA or CDDP was performed and the QOL of the patient improved. Pro-GRP and serum creatinine changed in parallel during the clinical course of 6 admissions. In conclusion, individualized therapy is necessary to increase survival time of SCLC patients with renal failure. Although chemotherapy is useful, further study is needed for the selection of suitable chemotherapeutic regimens, optimal dosage of each drug and the timing of HD.
authors.affiliation: Dept. of Internal Medicine, Osaka Prefectural General Hospital.
authors.forename: Takashi
authors.initials: T
authors.lastname: Obana
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Tanio
authors.forename: Masahiko
authors.initials: M
authors.lastname: Takenaka
authors.forename: Dai
authors.initials: D
authors.lastname: Watanabe
authors.forename: Masahiko
authors.initials: M
authors.lastname: Yanagita
authors.forename: Sumihiro
authors.initials: S
authors.lastname: Nakajima
authors.forename: Keiko
authors.initials: K
authors.lastname: Okuda
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Tsubakihara
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Fushimi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000493:pharmacokinetics; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000556:secondary; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D007680:Kidney Neoplasms / Q000150:complications / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D020364:Paraneoplastic Polyneuropathy / Q000188:drug therapy*; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000150:complications* / Q000628:therapy
chemical_list: D005047:Etoposide; D016190:Carboplatin